Literature DB >> 8627383

The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

J M Wilson1, S J Kish.   

Abstract

Although much evidence suggests that the brain dopamine transporter (DAT) is susceptible to dopaminergic regulation, only limited information is available for the vesicular monoamine transporter (VMAT2). In the present investigation, we used a chronic, unlimited-access, cocaine self-administration paradigm to determine whether brain levels of VMAT2, as estimated using [3H]dihydrotetrabenazine (DTBZ) binding, are altered by chronic exposure to a dopamine uptake blocker. Previously, we showed that striatal and nucleus accumbens DAT levels, as estimated by [3H]WIN 35,428 and [3H]GBR 12,935 binding, are altered markedly using this animal model (Wilson et al., 1994). However, in sequential sections from the same animals, [3H]DTBZ binding was normal throughout the entire rostrocaudal extent of the basal ganglia (including striatum and nucleus accumbens), cerebral cortex, and diencephalon, as well as in midbrain and brainstem monoamine cell body regions, both on the last day of cocaine access and after 3 weeks of drug withdrawal. These data provide additional evidence that VMAT2, unlike DAT, is resistant to dopaminergic regulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627383      PMCID: PMC6579154     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

1.  Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum.

Authors:  W Rostène; J W Boja; D Scherman; F I Carroll; M J Kuhar
Journal:  Eur J Pharmacol       Date:  1992-07-21       Impact factor: 4.432

2.  Effect of dose on cocaine self-administration behavior and dopamine levels in the nucleus accumbens.

Authors:  H O Pettit; J B Justice
Journal:  Brain Res       Date:  1991-01-18       Impact factor: 3.252

3.  Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier.

Authors:  H L Wiener; A Hashim; A Lajtha; H Sershen
Journal:  Eur J Pharmacol       Date:  1989-04-12       Impact factor: 4.432

4.  Long-term cocaine administration is not neurotoxic to cultured fetal mesencephalic dopamine neurons.

Authors:  B A Bennett; C E Hyde; J R Pecora; J E Clodfelter
Journal:  Neurosci Lett       Date:  1993-04-30       Impact factor: 3.046

5.  Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site.

Authors:  M R Kilbourn; P S Sherman; T Pisani
Journal:  Eur J Pharmacol       Date:  1992-05-27       Impact factor: 4.432

6.  Alterations in the dopaminergic receptor system after chronic administration of cocaine.

Authors:  M E Alburges; N Narang; J K Wamsley
Journal:  Synapse       Date:  1993-08       Impact factor: 2.562

7.  Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions.

Authors:  D Scherman
Journal:  J Neurochem       Date:  1986-08       Impact factor: 5.372

8.  Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine.

Authors:  L H Parsons; A D Smith; J B Justice
Journal:  Synapse       Date:  1991-09       Impact factor: 2.562

9.  Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease.

Authors:  H Schoemaker; C Pimoule; S Arbilla; B Scatton; F Javoy-Agid; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

10.  Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra.

Authors:  L Naudon; I Leroux-Nicollet; J Costentin
Journal:  Neurosci Lett       Date:  1994-05-23       Impact factor: 3.046

View more
  25 in total

1.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.

Authors:  Joshua S Beckmann; Emily D Denehy; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

Review 2.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

3.  Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine.

Authors:  Noah R Gubner; Cheryl Reed; Carrie S McKinnon; Tamara J Phillips
Journal:  Behav Brain Res       Date:  2013-08-28       Impact factor: 3.332

4.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

5.  Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography.

Authors:  Elissa M Strome; Ivan L Cepeda; Vesna Sossi; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

6.  Molecular imaging of cell transplantation in Parkinson's disease.

Authors:  Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04       Impact factor: 9.236

7.  Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Authors:  Rajesh Narendran; Hank P Jedema; Brian J Lopresti; Neale Scott Mason; Michael L Himes; Charles W Bradberry
Journal:  Biol Psychiatry       Date:  2014-06-23       Impact factor: 13.382

8.  Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2.

Authors:  K Schwartz; R Nachman; M Yossifoff; R Sapir; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

9.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

10.  Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Authors:  Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney
Journal:  Neuropsychopharmacology       Date:  2009-07-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.